Treatment for prurigo nodularis using upadacitinib

A 24 Week, Open-Label Study to Evaluate the Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Prurigo Nodularis

This study is testing if a new medication called upadacitinib can help people with moderate-to-severe prurigo nodularis feel better and improve their quality of life over 24 weeks.

Quick facts

• Phase: Phase 4
• Study type: Interventional
• Enrollment: 25 (estimated)
• Ages: 18 Years to 64 Years
• Sex: All
• Sponsor: Psoriasis Treatment Center of Central New Jersey (Academic / other)
• Drugs / interventions: upadacitinib
• Locations: 1 site (East Windsor, New Jersey)
• Trial ID: NCT06773403 on ClinicalTrials.gov

What this trial studies

This clinical trial is an open-label study involving 25 participants to evaluate the effectiveness of upadacitinib over a 24-week period in individuals suffering from moderate-to-severe prurigo nodularis. Participants must have had the condition for at least three months and show a significant number of lesions. The study aims to determine how well this medication can alleviate symptoms and improve the quality of life for affected patients.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-64 with a diagnosis of moderate-to-severe prurigo nodularis who have not responded to previous topical corticosteroid treatments.

Not a fit: Patients with mild prurigo nodularis or those who have not failed previous topical treatments may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce symptoms and improve the quality of life for patients with prurigo nodularis.

How similar studies have performed: While this specific approach is being evaluated in this trial, similar studies using upadacitinib for other conditions have shown promising results.

Eligibility criteria

Inclusion Criteria:

1. Male or female adult 18-64 years of age at time of screening.
2. Diagnosis of prurigo nodularis for ≥ 3 months.
3. Moderate-to-Severe prurigo nodularis as determined by at least 10 PN lesions on legs and/or arms and/or trunk at screening and baseline .
4. Failure of at least a 2-week course of medium to super potent TCS or TCS is not medically advisable for subject.
5. Females of childbearing potential must not have a positive serum pregnancy test at the Screening Visit and must have a negative urine pregnancy test at the Baseline Visit prior to study drug dosing. Note: subjects with borderline pregnancy test at Screening must have a serum pregnancy test ≥ 3 days later to determine eligibility.

   If female, subject must be postmenopausal OR permanently surgically sterile OR for females of childbearing potential practicing at least one protocol specified method of birth control, that is effective from the Baseline Visit through at least 30 days after the last dose of study drug. Female subject must not be pregnant, breastfeeding or considering becoming pregnant during the study or for approximately 30 days after the last dose of the study drug.
6. Subject is a candidate for systemic therapy per investigator discretion.
7. Able and willing to give written informed consent prior to performance of any study-related procedures.
8. Subject must be in general good health as judged by the Investigator, based on medical history, physical examination.

Exclusion Criteria:

1. Presence of skin condition other than prurigo nodularis or atopic dermatitis that may interfere with study assessments.
2. Diagnosis of active atopic dermatitis at screening and baseline.
3. PN secondary to medications.
4. PN secondary to medical conditions such as neuropathy or psychiatric disease.
5. Severe concomitant illness(es) under poor control that, in the investigator's judgment, would adversely affect the patient's participation in the study.
6. Severe renal conditions (eg, patients with uremia and/or on dialysis)
7. Participants with uncontrolled thyroid disease.
8. Active tuberculosis or non-tuberculous mycobacterial infection, or a history of incompletely treated tuberculosis unless documented adequately treated. Patients with latent TB at screening may be enrolled if tuberculosis treatment is initiated prior to first dose.
9. Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic infection, unless clinical and (if necessary) laboratory assessment have ruled out active infection before randomization.
10. Active chronic or acute infection (except HIV infection) requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before the screening visit or during the screening period.
11. Known or suspected immunodeficiency.
12. Active malignancy or history of malignancy within 5 years before the baseline visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.

Where this trial is running

East Windsor, New Jersey

• Eczema Treatment Center of New Jersey — East Windsor, New Jersey, United States (Recruiting)

Study contacts

• Study coordinator: Ashley Reed

Conditions Prurigo Nodularis